Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 13/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.71 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GABRP | O00591 | 1/20 | 0.61 |
| ▸ | GABRD | O14764 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GABRE | P78334 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iomazenil SCHEMBL29385986 | 1.00 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7334382 | 0.91 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10365966 | 0.89 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Sarmazenil SCHEMBL195304 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7329697 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9745968 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iomazenil (123I) SCHEMBL17022271 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iomazenil (123I) SCHEMBL29374678 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10627713 | 0.87 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL11887388 | 0.86 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0353754-B1 | RADIOACTIVELY MARKED BENZODIAZEPIN DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 1992-12-02 | — | — | EP | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250281535-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-09-11 | — | — | US | disclosed |
| EP-4401842-B1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2001089586-A2 | TC AND RE CARBONYL COMPLEXES FOR PERTECHNETATE AND PERRHENATE | MALLINCKRODT INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001000637-A1 | GROUP (VII) TRANSITION-METAL COMPLEXES WITH MULTIDENTATE AMINOPOLYCARBOXYLATE LIGANDS AND A KIT FOR PRODUCING THEM | MALLINCKRODT INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1019095-A1 | METHOD FOR THE PREPARATION OF FACIAL METAL TRICARBONYL COMPOUNDS AND THEIR USE IN THE LABELLING OF BIOLOGICALLY ACTIVE SUBSTRATES | Mallinckrodt Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0879606-A1 | Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates | PAUL SCHERRER INSTITUT (CH) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998048848-A1 | METHOD FOR THE PREPARATION OF FACIAL METAL TRICARBONYL COMPOUNDS AND THEIR USE IN THE LABELLING OF BIOLOGICALLY ACTIVE SUBSTRATES | MALLINCKRODT INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5096695-A | Diagnosis of brain disorders, cardiovascular diseases, epilepsy, psychosis | HOFFMANN-LAROCHE INC. (US) | 1992-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | GABRA1 879/4885GABRG2 1092/4885GABRB3 387/4885 |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRA1 8/4885GABRG2 14/4885GABRB3 9/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | GABRA1 1184/4885GABRG2 1329/4885GABRB3 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.